Skip to main content

Table 2 Extent of DFN-02 exposure overall and in subjects who completed the study

From: A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

 

Safety population (N  =  167)

Completers (n  =  134)

Daysa

 Mean (SD)

163.3 (48.9)

 

 Median

181

 

 Range

3–241

 

Monthsb

  

 Mean (SD)

5.4 (1.6)

 

 Median

6.0

 

 Range

0.1–8.0

 

Doses taken

3292

3031

Doses per patient

 Mean (SD)

19.7 (13.0)

22.6 (12.1)

 Median

18.0

20.5

 Range

(1–61)

(2–61)

Doses per patient (monthly)c

 Mean (SD)

3.6 (2.1)

3.7 (2.0)

 Median

3.3

3.4

 Range

0.3–10.2

0.3–10.2

  1. SD standard deviation
  2. aDate of study completion or early termination – date of enrollment +1
  3. bNumber of days in the study/30
  4. cNumber of total doses taken/number of months in the study
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us